Key result
Current pharmacotherapies, including ACE inhibitors and ARBs, leave a high residual burden of cardiovascular disease, with a 2005 United States overall death rate of 278.9 per 100,000 people.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This review discusses the therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases.
D espite the tremendous success obtained using the current pharmacotherapy, especially angiotensin (Ang)converting enzyme (ACE) inhibitors (ACEis) and Ang II receptor blockers (ARBs), the prevalence of cardiovascular diseases (CVDs) remains high around the world. The overall death rate in the United States alone in 2005 was 278.9 per 100 000 people.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2009) studied this question. Current pharmacotherapies, including ACE inhibitors and ARBs, leave a high residual burden of cardiovascular disease, with a 2005 United States overall death rate of 278.9 per 100,000 people.
Synapse has enriched 10 related papers. Consider them for comparative context: